Shares of Akcea Therapeutics were up more than 60 percent in trading after majority owner Ionis Pharmaceuticals announced it will acquire all outstanding shares of the company, which amounts to about 24 percent of available stock for $18.50 per share.
Sociétés des Produits Nestlé, a part of Nestlé Health Science, acquired the outstanding shares of California-based Aimmune for $2.6 billion in cash following years of increasing its financial position in the food allergy-focused company.
The Trump administration will purchase 150 million rapid coronavirus tests from Abbott Laboratories for about $750 million, a White House spokeswoman said.
Clinical diagnostics company Novacyt, one of many healthcare companies whose shares have surged during the pandemic, launched a test to differentiate between Covid-19 and common winter diseases.
Moderna Inc. said an analysis of the early-stage data of the company’s experimental Covid-19 vaccine showed mRNA-1273 induced immune responses in older adults that were similar to younger participants.
VBI Vaccines Inc. said the company expected to begin human testing of two experimental Covid-19 vaccine candidates at the end of the 2020.
The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) for Tricida’s experimental chronic kidney disease treatment veverimer.
British drugmaker AstraZeneca started testing an antibody-based cocktail for the prevention and treatment of Covid-19, adding to recent signs of progress on possible medical solutions to the disease caused by the novel coronavirus.
Gilead remdesivir study finds only marginal benefit for moderate COVID-19 patients (Reuters) – Moderately ill COVID-19 patients saw their condition improve after a 5-day course of Gilead Sciences Inc’s (GILD.O) […]
Shares of Pfizer Inc. and U.S.-listed shares of partner BioNTech SE rose after the companies released additional data for their experimental coronavirus vaccine and reiterated they were on track to seek a regulatory review in October.
